Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by 5AM Venture Management LLC

5AM Venture Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 7.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,629,765 shares of the company's stock after selling 122,409 shares during the quarter. Enliven Therapeutics makes up about 8.8% of 5AM Venture Management LLC's investment portfolio, making the stock its 2nd biggest position. 5AM Venture Management LLC owned 3.34% of Enliven Therapeutics worth $36,670,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ELVN. Invesco Ltd. raised its holdings in shares of Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after buying an additional 508 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. MetLife Investment Management LLC raised its position in Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock valued at $307,000 after buying an additional 1,980 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 21st.

Insider Activity

In related news, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the sale, the chief executive officer now owns 990,392 shares of the company's stock, valued at $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,111 shares of company stock worth $1,516,746. Corporate insiders own 29.20% of the company's stock.

Enliven Therapeutics Price Performance

ELVN stock traded down $1.37 during mid-day trading on Wednesday, reaching $18.33. The company had a trading volume of 40,650 shares, compared to its average volume of 260,185. The company has a market capitalization of $899.13 million, a price-to-earnings ratio of -9.64 and a beta of 1.07. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03. The stock has a 50 day simple moving average of $19.16 and a two-hundred day simple moving average of $22.26.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.